How to buy Rigel Pharmaceuticals stock | 2.74

Rigel Pharmaceuticals, Inc is a biotechnology business based in the US. Rigel Pharmaceuticals shares (RIGL) are listed on the NASDAQ and all prices are listed in US Dollars. Rigel Pharmaceuticals employs 163 staff and has a trailing 12-month revenue of around USD$105.6 million.

How to buy shares in Rigel Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Rigel Pharmaceuticals. Find the stock by name or ticker symbol: RIGL. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Rigel Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$2.74, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Rigel Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Rigel Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Rigel Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Rigel Pharmaceuticals's share price has had significant positive movement.

Its last market close was USD$2.74, which is 16.06% up on its pre-crash value of USD$2.3 and 122.76% up on the lowest point reached during the March crash when the shares fell as low as USD$1.23.

If you had bought USD$1,000 worth of Rigel Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$612.43 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,173.46.

Rigel Pharmaceuticals share price

Use our graph to track the performance of RIGL stocks over time.

Rigel Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-11-19.

Latest market close	USD$2.74
52-week range	USD$1.23 - USD$3.89
50-day moving average	USD$2.5769
200-day moving average	USD$2.3205
Wall St. target price	USD$7.33
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.352

Buy Rigel Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Rigel Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Rigel Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Rigel Pharmaceuticals price performance over time

Historical closes compared with the close of $2.74 from 2020-11-16

1 week (2020-11-16)	2.74
1 month (2020-10-26)	12.30%
3 months (2020-08-24)	15.13%
6 months (2020-05-22)	50.55%

1 year (2019-11-22)	19.13%
2 years (2018-11-23)	-0.36%
3 years (2017-11-24)	-35.53%
5 years (2015-11-24)	-12.18%

Rigel Pharmaceuticals financials

Revenue TTM	USD$105.6 million
Gross profit TTM	USD$5.5 million
Return on assets TTM	-12.31%
Return on equity TTM	-46.23%
Profit margin	-26.25%
Book value	$0.302
Market capitalisation	USD$451.2 million

TTM: trailing 12 months

Shorting Rigel Pharmaceuticals shares

There are currently 24.4 million Rigel Pharmaceuticals shares held short by investors – that's known as Rigel Pharmaceuticals's "short interest". This figure is 18% up from 20.7 million last month.

There are a few different ways that this level of interest in shorting Rigel Pharmaceuticals shares can be evaluated.

Rigel Pharmaceuticals's "short interest ratio" (SIR)

Rigel Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Rigel Pharmaceuticals shares currently shorted divided by the average quantity of Rigel Pharmaceuticals shares traded daily (recently around 2.3 million). Rigel Pharmaceuticals's SIR currently stands at 10.78. In other words for every 100,000 Rigel Pharmaceuticals shares traded daily on the market, roughly 10780 shares are currently held short.

However Rigel Pharmaceuticals's short interest can also be evaluated against the total number of Rigel Pharmaceuticals shares, or, against the total number of tradable Rigel Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rigel Pharmaceuticals's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Rigel Pharmaceuticals shares in existence, roughly 140 shares are currently held short) or 0.1674% of the tradable shares (for every 100,000 tradable Rigel Pharmaceuticals shares, roughly 167 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Rigel Pharmaceuticals.

Find out more about how you can short Rigel Pharmaceuticals stock.

Rigel Pharmaceuticals share dividends

We're not expecting Rigel Pharmaceuticals to pay a dividend over the next 12 months.

Have Rigel Pharmaceuticals's shares ever split?

Rigel Pharmaceuticals's shares were split on a 1:9 basis on 25 June 2003. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rigel Pharmaceuticals shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Rigel Pharmaceuticals shares which in turn could have impacted Rigel Pharmaceuticals's share price.

Rigel Pharmaceuticals share price volatility

Over the last 12 months, Rigel Pharmaceuticals's shares have ranged in value from as little as $1.23 up to $3.89. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rigel Pharmaceuticals's is 1.4064. This would suggest that Rigel Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Rigel Pharmaceuticals overview

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trials for warm autoimmune hemolytic anemia; R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trials for autoimmune and inflammatory diseases; and R552, a receptor-interacting protein kinase Inhibitor that is in phase I clinical trials for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Frequently asked questions

• What percentage of Rigel Pharmaceuticals is owned by insiders or institutions?

  Currently 0.308% of Rigel Pharmaceuticals shares are held by insiders and 85.472% by institutions.

• How many people work for Rigel Pharmaceuticals?

  Latest data suggests 163 work at Rigel Pharmaceuticals.

• When does the fiscal year end for Rigel Pharmaceuticals?

  Rigel Pharmaceuticals's fiscal year ends in December.

• Where is Rigel Pharmaceuticals based?

  Rigel Pharmaceuticals's address is: 1180 Veterans Boulevard, South San Francisco, CA, United States, 94080

• What is Rigel Pharmaceuticals's ISIN number?

  Rigel Pharmaceuticals's international securities identification number is: US7665596034

• What is Rigel Pharmaceuticals's CUSIP number?

  Rigel Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 766559108